Israeli AI drug discovery, Protai, raises $ 8 million

The company has built an end-to-end AI-based platform that extensively maps a disease course at the protein level.

Israeli AI-powered drug discovery firm Protai today announced the completion of a $ 8 million seed funding round, led by Grove Ventures and Pitango HealthTech. The company said the new investment will be used to develop its platform, accelerate its discovery programs and improve partnerships with pharmaceutical companies.

Protai, which was first founded last year, has built an end-to-end AI-based platform that comprehensively maps the disease course at the protein level, improving the ability to observe cellular function and thereby improving the way new drugs are detected. . This approach allows Protai to increase the accuracy of drug discovery and improve the development process, saving time significantly and lowering research and development costs.

Protais co-founder and CEO Eran Seger said: “Protai’s platform is like a unique compass to guide drug discovery. We systematically map diseases at the protein level to create a whole new layer of functional information that enables us to identify therapeutic and diagnostic aims to better combat a wide range of complex diseases. “

Protai claims to have created the world’s largest and most diverse proteomic database with over 50,000 clinical samples by harmonizing large clinical datasets, as well as healthy samples from various organs and indications. This allows Protai to establish a baseline and then accurately simulate biological functional processes for a range of diseases and accelerate drug research and development through clinical and preclinical phases.

Published by Globes, Israel business news – en.globes.co.il – January 5, 2022.

© Copyright by Globes Publisher Itonut (1983) Ltd., 2022.


Portai team Photo: David Karp

Portai team Photo: David Karp

Give a Comment